Applied Therapeutics Inc(APLT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.1 | Insider Own | 5.69% | Shs Outstand | 144.3M | Perf Week | - |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 24.19% | Insider Trans | -0.52% | Shs Float | 136.1M | Perf Month | 2.28% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.2 | Inst Own | 58.5% | Short Float | 1.07% | Perf Quarter | -88.81% |
| Income | -0.02B | P/S | 14.86 | EPS this Y | 18.42% | Inst Trans | - | Short Ratio | 0.09 | Perf Half Y | -77.19% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -25.74% | Short Interest | 1.45M | Perf YTD | 3% |
| Book/sh | 0 | P/C | 1.24 | EPS past 3/5Y | 43.17% 26.57% | ROE | -680.47% | 52W High | -93.13% ($1.50) | Perf Year | -82.44% |
| Cash/sh | 0.08 | P/FCF | - | Sales past 3/5Y | - | ROIC | -1232.2% | 52W Low | 14.44% ($0.09) | Perf 3Y | -91.04% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 92.43% | Gross Margin | 59.6% | Volatility(W/M) | 11.03% 8.09% | Perf 5Y | -99.63% |
| Dividend TTM | - | EV/Sales | 5.41 | Sales Y/Y TTM | - | Oper. Margin | -9840.3% | ATR (14) | 0.01 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.96 | EPS Q/Q | 72.54% | Profit Margin | -1813.8% | RSI (14) | 35.58 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.96 | Sales Q/Q | 719.67% | SMA20 | 2.41% ($0.1) | Beta | 2.07 | Target Price | $0.25 |
| Payout | - | Debt/Eq | - | Earnings | 2025/11/13 | SMA50 | -31.2% ($0.15) | Rel Volume | 0 | Prev Close | $0.1 |
| Employees | 35 | LT Debt/Eq | - | EPS/Sales Surpr. | 7.8% 200.03% | SMA200 | -77.78% ($0.45) | Avg Volume(3M) | 15.59M | Price | $0.1 |
| IPO | 2019/5/14 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
🔬 Applied Therapeutics (APLT) is a biotechnology company that discovers and conducts clinical trials on small-molecule candidates targeting specific enzymes to treat serious and rare metabolic and neurological disorders.
Over the past 1 year, on the lower side
93% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
APLT has weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +18.4% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,486. Peers typically go for $204.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.6%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 58.5%.
Tap to view numbers
It ranks #476 of 596 in the industry
Based on market cap of $15M.
APLT#476 Applied Therapeutics Inc $15M PER - 
AKTX#476 Akari Therapeutics Plc ADR $14M PER - 
GUTS#477 Fractyl Health Inc $14M PER - 
NCEL#478 NewcelX Ltd $14M PER - 
BCDA#479 BioCardia Inc $14M PER - 
FAQ
What kind of company is APLT?
APLT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of APLT?
The market cap of APLT is approximately $15M, ranking 5,366 within its sector.
What is the 52-week high and low for APLT?
APLT has recorded a 52-week high of $1.50 and a low of $0.09.
